Pfizer to buy Biohaven for $11.6B: 4 things to know

By Becker's Hospital Review - Healthcare News in Becker's Hospital Review, Channels, Featured
May 10, 2022

Pfizer has agreed to acquire the migraine treatment maker Biohaven Pharmaceuticals for $11.6 billion, the drugmaker said May 10.

Read the full post on Becker's Hospital Review - Healthcare News

Becker's Hospital Review - Healthcare News